A new and ambitious patient-focused delivery plan was released today by the Medicines and Health Products Regulatory Agency (MHRA).
âPutting Patients First: A New Era for Our Agency,â ensures that the agency is constantly focused on achieving meaningful patient outcomes, protecting public health through regulatory excellence and science and become a truly leading enabling regulator.
At the heart of the plan is how the MHRA will bring together its scientific and regulatory expertise to help facilitate the life sciences sector and health services in the UK; develop new regulatory frameworks; quickly realize the benefits of new therapies and innovative technologies such as artificial intelligence (AI), to improve patient outcomes; and ensuring the continued safety, quality and efficacy of drugs and medical devices.
The plan recognizes the significant challenges the agency will need to overcome to achieve its ambition. Priorities include implementing the recommendations set out in the Independent Review of the Safety of Medicines and Medical Devices by ensuring that patients are listened to and involved more systematically.
Another major challenge will be strengthening international regulatory relations and improving partnerships with the wider health system now that the UK has left the EU; the agency will need to work quickly to evolve regulatory frameworks so that they remain fit for purpose in an era of fast-paced advanced scientific developments.
Underpinning this benefit is the creation of a new business model that provides a financially sustainable future that will meet the growing expectations of patients, healthcare professionals, partners, the pharmaceutical industry, government and parties. industry stakeholders at large and not for profit.
Implementation of the plan will build on the MHRA’s exceptional service to the UK public during the COVID-19 pandemic and the challenges it continues to pose to global science and healthcare.
The plan defines 14 objectives grouped into 6 central themes:
- Scientific innovation
- Health care access
- Patient safety
- Dynamic organization
- Collaborative partnerships
- Financial viability
Above all this, for each staff member, the priority is to provide better patient and public involvement and to put patients first.
Dr June Raine CBE, Director General of the Medicines and Health Products Regulatory Agency, said:
Our response to the COVID-19 pandemic is positive proof that we can meet challenges with fresh thinking and innovative approaches – fulfilling our responsibilities to patients first and foremost, as outlined in the Independent Safety Review medicines and medical devices, and opening up the many opportunities now that the UK has left the EU, with a real advantage for the brilliant UK life science industry and for healthcare.
This plan is our response to these challenges and more. We have shown that we can not only excel under pressure and in exceptional circumstances, but also where we can take direct action to support and protect patients and improve health outcomes.
It marks a radical shift in our efforts to build a leading organization, bringing together excellence in science and regulation to serve patients and public health to the best of our ability.
Stephen Lightfoot, President of the Medicines and Health Products Regulatory Agency, said:
We are keenly aware of the many opportunities and challenges we face, but we are confident in the course we have set, our scientific expertise and our vision for progressive regulation to support the global life science industry.
Our delivery plan clearly articulates our ambition and prioritizes the actions we take to achieve it: embed our undeniable strengths in science and regulation; building the UK and the international partnerships we need to support our delivery; and make the decisions necessary to improve our organizational resilience. These actions will allow us to dramatically improve patient engagement and outcomes through the faster introduction of safe and effective medical products for patients around the world.
Innovation Minister Lord Bethell said:
During the many challenges posed by COVID-19, the UK’s brilliant life sciences and health sectors have led the way for scientific innovation, rapidly developing life-saving vaccines and treatments that have helped reverse the trend of the pandemic.
The MHRA has played an absolutely crucial role in the success of our vaccination program by thoroughly evaluating and batch testing all vaccines, allowing the UK to be the first country in the world to deploy an approved vaccine – which has avoided over seven million infections. and 27,000 deaths in England alone.
MHRA’s new delivery plan explains how the UK will apply lessons learned from the pandemic and seize the opportunity for innovation now that we have left the EU to ensure that NHS patients can benefit first from all medical innovations.
Read the MHRA 2021-2023 delivery plan
Notes to Editors:
- The Medicines and Health Products Regulatory Agency is responsible for regulating all medicines and medical devices in the UK making sure they work and are sufficiently safe. All of our work is backed by solid, fact-based judgments to ensure that the benefits justify the risks.
- The 2021-2023 delivery plan replaces our current 2018-2023 business plan.